BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Afzali A, Furtner D, Melsheimer R, Molloy PJ. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. Adv Ther 2021;38:2077-93. [PMID: 33745111 DOI: 10.1007/s12325-021-01688-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Horta-baas G. Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake? PROM 2022;Volume 13:79-95. [DOI: 10.2147/prom.s256715] [Reference Citation Analysis]
2 Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin 2022;:1-33. [PMID: 35125053 DOI: 10.1080/03007995.2022.2037846] [Reference Citation Analysis]
3 Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmol Ther 2022. [PMID: 35278204 DOI: 10.1007/s40123-022-00488-w] [Reference Citation Analysis]
4 Tolonen HM, Falck J, Kurki P, Ruokoniemi P, Hämeen-Anttila K, Shermock KM, Airaksinen M. Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review. BioDrugs 2021. [PMID: 34398421 DOI: 10.1007/s40259-021-00493-8] [Reference Citation Analysis]